Observational study of ATTR amyloidosis treatment patterns
Part of Heart & circulation clinical trials.
This study looks at the health records of people with ATTR amyloidosis to understand how the disease is treated and what happens over time. It helps doctors learn more about this condition so they can improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a medical record showing a diagnosis of amyloidosis, or you have received a treatment specifically for ATTR amyloidosis, or you have had a biopsy that confirmed ATTR amyloidosis.
- You do not have primary (AL) or secondary (AA) amyloidosis (other types of amyloidosis).
- You have not had a stem cell transplant or at least two rounds of chemotherapy or autoimmune disease drugs (which are often used for AL or AA amyloidosis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an observational study (no study drug) for people with transthyretin (TTR)–mediated amyloidosis, including people who carry certain gene changes before symptoms begin. It may help researchers better understand how the disease affects health over time and what to measure in future treatments.
This study follows patients with ATTR amyloidosis over time to understand how the disease affects them. It does not test a new treatment—instead, it asks you to fill out questionnaires about your health and symptoms to help doctors learn more about the condition.
This study looks at how a heart medication (tafamidis) affects amyloid protein levels in the blood over time. It may help doctors understand how well the treatment works for people with a specific type of heart disease caused by amyloid buildup (ATTR-CM).
This study collects information from people with a specific type of heart disease called cardiac amyloidosis (AL or ATTR type). By joining a registry, you help doctors learn more about these conditions and how to better treat them.
This study is observing people with amyloidosis or those who carry a specific gene mutation (transthyretin) to learn more about the condition. It does not test any new treatment, but may help researchers understand how the disease affects people.
This study follows patients with a specific type of heart amyloidosis (wild-type ATTR) who are taking or could start the drug tafamidis. It aims to learn more about how the condition and treatment affect people over time.
Hear when a new ATTR Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.